NCT03197155View on ClinicalTrials.gov

Direct-acting Antivirals and Hepatocellular Carcinoma Recurrence

CompletedOBSERVATIONAL
Enrollment

68

Participants

Timeline

Start Date

June 1, 2016

Primary Completion Date

January 31, 2017

Study Completion Date

March 31, 2017

Conditions
Hepatocellular CarcinomaHepatitis CDirect Acting Antivirals
Interventions
DRUG

Direct Acting Antivirals against hepatitis C virus infection

The cohort includes cirrhotic patients infected with HCV and successfully treated for their first history of hepatocellular carcinoma. Some of these patients were treated with direct-acting antivirals for their HCV infection while the others did not receive any direct-acting antivirals treatment during the follow-up period.

All Listed Sponsors
lead

Hospices Civils de Lyon

OTHER

NCT03197155 - Direct-acting Antivirals and Hepatocellular Carcinoma Recurrence | Biotech Hunter | Biotech Hunter